The FDA on December 14, 2018 approved HERZUMA® as a biosimilar to HERCEPTIN® (Trastuzumab) for patients with HER2-overexpressing breast cancer. HERZUMA® is a product of Celltrion Inc.
Other Pages – Bottom Ad
Advertisement
Subscribe
Other Pages – Top Ad
Advertisement